In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Evolution of cardiovascular risk factors, analytical markers and functional capacity. Are the benefits of phase II of the cardiac rehabilitation program maintained in phase III?

Session Poster Session 2

Speaker Belen Garcia Magallon

Congress : ESC Preventive Cardiology (Formerly EuroPrevent) 2019

  • Topic : preventive cardiology
  • Sub-topic : Secondary Prevention
  • Session type : Poster Session
  • FP Number : P533

Authors : N G Uribe Heredia (Guadalajara,ES), J Balaguer Recena (Guadalajara,ES), LG Piccone Saponara (Ciudad Real,ES), H Alvaro Fernandez (Guadalajara,ES), R Arroyo Espliguero (Guadalajara,ES), E Vallejo Sacristan (Guadalajara,ES), J Benitez Peyrat (Guadalajara,ES), C Solorzano Guillen (Guadalajara,ES), ME Jimenez Martinez (Guadalajara,ES), E Novo Garcia (Guadalajara,ES), MA San Martin Gomez (Guadalajara,ES), I Rodriguez Guinea (Guadalajara,ES), M Viana Llamas (Guadalajara,ES), B Garcia Magallon (Guadalajara,ES), E Diaz Caraballo (Guadalajara,ES)

Authors:
N G Uribe Heredia1 , J Balaguer Recena2 , LG Piccone Saponara3 , H Alvaro Fernandez1 , R Arroyo Espliguero2 , E Vallejo Sacristan1 , J Benitez Peyrat2 , C Solorzano Guillen2 , ME Jimenez Martinez2 , E Novo Garcia2 , MA San Martin Gomez2 , I Rodriguez Guinea2 , M Viana Llamas2 , B Garcia Magallon2 , E Diaz Caraballo2 , 1University Hospital of Guadalajara, Cardiac Rehabilitation Unit - Guadalajara - Spain , 2University Hospital of Guadalajara, Department of Cardiology - Guadalajara - Spain , 3Hospital General de Ciudad Real, Nefrology - Ciudad Real - Spain ,

Citation:

INTRODUCTION: The cardiac rehabilitation (CR) program has proven to be useful in the control of modifiable risk factors after phase II by adjusting treatment, physical training and lifestyle changes, but there is little information on if this benefit is maintained over time during phase III.
METHODS: Prospective observational study. 165 patients were studied, consecutively included in the CR program from March 2015 to November 2017. Demographic, clinical, analytical and ergometry variables were evaluated prior to the CR, at the end of phase II and at 6 months in the phase III of the CR program. Results are presented as mean±SD for continuous variables and as percentages for categorical data. Comparisons between continuous variables were analyzed using the paired T-test.
RESULTS: A total of 165 patients were analyzed. Prior to phase II of the CR program, they had a mean of 58.1±9.5 years, 84.8% men, 90.9% ischemic heart disease, 49.7% hypertension, dyslipidemia 69,7%, 22.4% diabetics, 59.4% smokers, mean LVEF 55.8±10%. According to AACVPR criteria, 16,4% of patients had a high risk and 44,2% had an intermediate risk. Prior to the CR program, 50.9% were in functional classes II-III of the NYHA, at the end of phase II this percentage was reduced to 12.1% and at 7,6±2,8 months from phase III the 13.8% of the patients was in functional class II-III of the NYHA. Study variables are depicted in Table 1.
CONCLUSIONS: In our setting, the benefit on the different cardiovascular risk factors, prognostic markers such as the levels of the C-Reactive protein and the B-Type natriuretic peptide, as well as in the functional class obtained at the end of phase II of the rehabilitation program cardiac is maintained at 7.6 months of phase III, even higher levels of HDL cholesterol are observed.

Variables

PRE

CR

PHASE

II

PHASE

III

P

Body mass index (BMI)

29,1±4,7

28,7±4,6

28,6±4,8

0,70

Systolic blood pressure at rest(mmHg)

123,7±15,7

119,1±12,8

119,2±11,8

0,93

Diastolic blood pressure at rest(mmHg)

75,5±8,7

71,7+6,7

72,7+7,3

0,13

Resting heart rate(beats per minute)

71,1±12,1

63,8±8,7

64,9±9,8

0,11

Functional capacity(MET)

8,1±2,5

10,0+2,7

9,9+2,8

0,17

Recovery time(beats in the first minute)

15,5±8,4

18,5±8,9

18,1±9,3

0,61

LDL cholesterol (mg/dl)

82,9±31,2

71,0±25,4

72,3±27,3

0,53

HDL cholesterol (mg/dl)

39,5±11,1

42,4±11,8

43,7±11,9

0,02

C-Reactive protein (mg/l) (CRP)

3,8±6,2

2,4±3,8

2,7±4,8

0,45

B-Type natriuretic peptide (pg/ml)

92,5±148,3

72,0±134,6

79,1±230,1

0,51

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are